RPS3A

Small ribosomal subunit protein eS1 · P61247 · RPS3A on Sugi Atlas →

3,623 patent compounds predicted against RPS3A, 1,889 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPS3A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA	PHASE4	COMPLETED
Tacrolimus Treatment for Refractory PRCA	PHASE4	UNKNOWN
Sirolimus Treatment for Refractory PRCA	PHASE4	COMPLETED
Proteome-based Personalized Immunotherapy of Glioblastoma	PHASE2/PHASE3	UNKNOWN
Proteome-based Immunotherapy of Lung Cancer Brain Metastases	PHASE2/PHASE3	UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag	PHASE1/PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care	nan	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
RibOSE - Glucose and Resistance Exercise Training	nan	COMPLETED
LINC00511/miR-185-3p Axis and miR-301a-3p Markers for Breast Cancer Diagnosis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPS3A binder may also engage these)

Protein	Name	Similarity
P49242	—	1.000	P49242 →
Q4R4Z6	—	1.000	Q4R4Z6 →
G1SS70	—	1.000	G1SS70 →
Q6PBY1	—	1.000	Q6PBY1 →
A8E604	—	1.000	A8E604 →
Q4T8S6	—	1.000	Q4T8S6 →
O73813	—	1.000	O73813 →
B5FZS9	—	1.000	B5FZS9 →
O43999	—	1.000	O43999 →
B5DGL6	—	1.000	B5DGL6 →
Q56JV9	—	1.000	Q56JV9 →
P33444	—	1.000	P33444 →
Q64FN2	—	1.000	Q64FN2 →
P97351	—	1.000	P97351 →
A2Q0R8	—	1.000	A2Q0R8 →
Q98TX2	—	1.000	Q98TX2 →
B0KW94	—	1.000	B0KW94 →
Q801S3	—	1.000	Q801S3 →
A5JSW9	—	1.000	A5JSW9 →
P49397	—	1.000	P49397 →
Q285L8	—	1.000	Q285L8 →
Q4KTD9	—	1.000	Q4KTD9 →
Q0UFP1	—	1.000	Q0UFP1 →
A7L6A0	—	1.000	A7L6A0 →
Q2GW51	—	1.000	Q2GW51 →
B2B5P2	—	1.000	B2B5P2 →
A8HS48	—	1.000	A8HS48 →
A9USH8	—	1.000	A9USH8 →
A7S3J7	—	1.000	A7S3J7 →
Q642T2	—	1.000	Q642T2 →